AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$ELTP

Dash Barry H purchased $9K of ELTP

Dash Barry H purchased 30,000 shares of ELITE PHARMACEUTICALS INC /NV/ (ELTP) at $0.29 on 2026-08-19.

Original reporting
SEC EDGAR · Dash Barry H
Published Sep 10, 2026, 5:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 5:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ELTP
Neutral
high confidence
Mentioned
$ELTP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELTPNeutralLow
01

Why it matters

The purchase adds to the director's stake, raising holdings to over 3.2 million shares.

02

Market read

Minor insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical milestones not disclosed in this filing.

Relevance 4/10Novelty 5/10Timing: filed Sep 10, 2026

Background

Form 4 filings disclose insider trades; investors monitor them for signals.

Company-level read

Ticker impact

$ELTPNeutralHigh confidence
Context

Director Dash Barry H bought 30,000 shares for $8,610 in a Form 4 filing.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

Purchase size is tiny relative to total holdings and market cap; unlikely to move price.

Market effects

Sector

No immediate sector impact; insider activity is company‑specific.

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider buying could be a subtle bullish signal despite small size.

Key entities

  • Company
    Elite Pharmaceuticals Inc

    Biopharmaceutical company listed on Nasdaq under ELTP.

  • Insider
    Dash Barry H

    Director of Elite Pharmaceuticals who made the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ELTP insider trading history →

Related articles

AUG 13
$ELTPLow

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026

ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026 and Provides Conference Call Information Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, NJ – August 13, 2026: Elite P

SEC EDGAR 8-K2 min
JUN 29
$ELTPLow

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026

ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001053369 0001053369 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2026

SEC EDGAR 8-K2 min